Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypertriglyceridemia and Cardiovascular Risk.

IF 8.4 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS European journal of preventive cardiology Pub Date : 2024-12-04 DOI:10.1093/eurjpc/zwae388
Chen Gurevitz, Robert S Rosenson
{"title":"Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypertriglyceridemia and Cardiovascular Risk.","authors":"Chen Gurevitz, Robert S Rosenson","doi":"10.1093/eurjpc/zwae388","DOIUrl":null,"url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of liver conditions ranging from simple steatosis to the more severe metabolic dysfunction-associated steatohepatitis (MASH). MASLD is strongly linked to insulin resistance disorders, with a high prevalence among patients with type 2 diabetes. Long-term complications include liver cirrhosis, liver cancer, and cardiovascular disease. This article elucidates the complex interplay between hypertriglyceridemia, obesity, insulin resistance, and MASLD and provides an exploration of various etiologies, including genetic predispositions and secondary factors such as diabetes, medication use, and alcohol consumption. While MASLD treatment remains an unmet need, multiple pharmacological therapies are targeting hypertriglyceridemia and MASLD, including statins, peroxisome proliferator-activated receptors (PPARs) agonists, biguanides, incretins, and emerging therapies including angiopoietin-like (ANGPTL) 3 and apolipoprotein (APO) C-III inhibitors, fibroblast growth factor (FGF) 21 analogues, and thyroid hormone receptor agonists. By examining these interconnected facets, this review offers insights into potential therapeutic strategies for MASLD and associated comorbidities.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of preventive cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/eurjpc/zwae388","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of liver conditions ranging from simple steatosis to the more severe metabolic dysfunction-associated steatohepatitis (MASH). MASLD is strongly linked to insulin resistance disorders, with a high prevalence among patients with type 2 diabetes. Long-term complications include liver cirrhosis, liver cancer, and cardiovascular disease. This article elucidates the complex interplay between hypertriglyceridemia, obesity, insulin resistance, and MASLD and provides an exploration of various etiologies, including genetic predispositions and secondary factors such as diabetes, medication use, and alcohol consumption. While MASLD treatment remains an unmet need, multiple pharmacological therapies are targeting hypertriglyceridemia and MASLD, including statins, peroxisome proliferator-activated receptors (PPARs) agonists, biguanides, incretins, and emerging therapies including angiopoietin-like (ANGPTL) 3 and apolipoprotein (APO) C-III inhibitors, fibroblast growth factor (FGF) 21 analogues, and thyroid hormone receptor agonists. By examining these interconnected facets, this review offers insights into potential therapeutic strategies for MASLD and associated comorbidities.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
代谢功能障碍相关的脂肪变性肝病、高甘油三酯血症和心血管风险。
代谢功能障碍相关性脂肪性肝病(MASLD)包括一系列肝病,从单纯的脂肪变性到更严重的代谢功能障碍相关性脂肪性肝炎(MASH)。MASLD与胰岛素抵抗紊乱密切相关,在2型糖尿病患者中发病率很高。长期并发症包括肝硬化、肝癌和心血管疾病。本文阐明了高甘油三酯血症、肥胖、胰岛素抵抗和 MASLD 之间复杂的相互作用,并探讨了各种病因,包括遗传倾向和继发因素,如糖尿病、药物使用和饮酒。虽然 MASLD 的治疗仍是一项尚未满足的需求,但目前有多种药物疗法可用于治疗高甘油三酯血症和 MASLD,包括他汀类药物、过氧化物酶体增殖激活受体 (PPAR) 激动剂、双胍类药物、吲哚类药物,以及血管生成素样 (ANGPTL) 3 和脂蛋白 (APO) C-III 抑制剂、成纤维细胞生长因子 (FGF) 21 类似物和甲状腺激素受体激动剂等新兴疗法。通过研究这些相互关联的方面,本综述为 MASLD 及相关合并症的潜在治疗策略提供了见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
European journal of preventive cardiology
European journal of preventive cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
12.50
自引率
12.00%
发文量
601
审稿时长
3-8 weeks
期刊介绍: European Journal of Preventive Cardiology (EJPC) is an official journal of the European Society of Cardiology (ESC) and the European Association of Preventive Cardiology (EAPC). The journal covers a wide range of scientific, clinical, and public health disciplines related to cardiovascular disease prevention, risk factor management, cardiovascular rehabilitation, population science and public health, and exercise physiology. The categories covered by the journal include classical risk factors and treatment, lifestyle risk factors, non-modifiable cardiovascular risk factors, cardiovascular conditions, concomitant pathological conditions, sport cardiology, diagnostic tests, care settings, epidemiology, pharmacology and pharmacotherapy, machine learning, and artificial intelligence.
期刊最新文献
Cardiovascular disease and stroke prevention educational-behavioural programs for culturally and/or linguistically diverse communities: a systematic review and meta-analysis. Effects of cardiac rehabilitation on the severity of angina, health-related quality of life, and exercise capacity among adults living with microvascular angina: a systematic review and meta-analysis. Letter to the Editor: A Note on Base Rates and Applicability of Screeners of Psychological Disorder in Adults with Congenital Heart Disease. Cardiovascular benefit of statin use against air pollutant exposure in older adults. RE: Ambient temperature and risk of cardiovascular and respiratory adverse health outcomes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1